Aromatase inhibitors in breast cancer. [N Engl J Med. 2003] - PubMed

Review [Aromatase inhibitors]. [Pol Arch Med Wewn. 2004]
Review [Aromatase inhibitors].
Krysiak R, Okopień B, Herman ZS. Pol Arch Med Wewn. 2004 Mar; 111(3):375-84.
Review The therapeutic potential of aromatase inhibitors. [Expert Opin Investig Drugs. 2003]
Review The therapeutic potential of aromatase inhibitors.
Miller WR, Jackson J. Expert Opin Investig Drugs. 2003 Mar; 12(3):337-51.
Review Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. [Drugs. 2002]
Review Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Goss PE, Strasser K. Drugs. 2002; 62(6):957-66.
Review Use of aromatase inhibitors in breast carcinoma. [Endocr Relat Cancer. 1999]
Review Use of aromatase inhibitors in breast carcinoma.
Santen RJ, Harvey HA. Endocr Relat Cancer. 1999 Mar; 6(1):75-92.
Review Aromatase inhibitors for breast cancer: pharmacoeconomic considerations. [Expert Opin Pharmacother. 2001]
Review Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
Higa GM. Expert Opin Pharmacother. 2001 Jun; 2(6):987-95.

Regression of late onset choroidal metastasis from a breast carcinoma with letrozole. [Case Report Ophthalmol. 2011]
Regression of late onset choroidal metastasis from a breast carcinoma with letrozole.
Cancino R, Vela JI, Sullivan I, Buil JA, Muñoz CA. Case Report Ophthalmol. 2011 Sep; 2(3):382-6. Epub 2011 Dec 10.
Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer. [Breast Cancer (Auckl). 2011]
Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer.
Dyar S, Moreno-Aspitia A. Breast Cancer (Auckl). 2011; 5:239-46. Epub 2011 Nov 28.
Pharmacoeconomic considerations in the treatment of breast cancer. [Clinicoecon Outcomes Res. 2010]
Pharmacoeconomic considerations in the treatment of breast cancer.
Pallis A, Tsiantou V, Simou E, Maniadakis N. Clinicoecon Outcomes Res. 2010; 2:47-61. Epub 2010 Jun 15.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Aromatase inhibitors in breast cancer.
Aromatase inhibitors in breast cancer.
N Engl J Med. 2003 Jun 12 ;348(24):2431-42.

PubMed
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer fam...
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
Hum Mutat. 2001 Dec ;18(6):545.

PubMed
Identification and quantification of N-linked glycoproteins using hydrazide chem...
Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.
Nat Biotechnol. 2003 Jun ;21(6):660-6. Epub 2003 May 18 .

PubMed
Transcriptional regulatory networks in Saccharomyces cerevisiae.
Transcriptional regulatory networks in Saccharomyces cerevisiae.
Science. 2002 Oct 25 ;298(5594):799-804.

PubMed
Breast cancers with brain metastases are more likely to be estrogen receptor neg...
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
Am J Surg Pathol. 2006 Sep ;30(9):1097-104.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed